Radius Health (RDUS) Shares are Up 4.18%

Radius Health (RDUS) : Traders are bullish on Radius Health (RDUS) as it has outperformed the S&P 500 by a wide margin of 3.03% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 3.66%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 4.18% in the last 1 week, and is up 2.89% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The stock has recorded a 20-day Moving Average of 2.84% and the 50-Day Moving Average is 20.14%.The 200 Day SMA reached 35.44%. Radius Health, Inc. is up 43.48% in the last 3-month period. Year-to-Date the stock performance stands at -8.09%.


Radius Health (NASDAQ:RDUS): After opening at $56.26, the stock dipped to an intraday low of $55.6 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $57.71 and the buying power remained strong till the end. The stock closed at $56.56 for the day, a gain of 1.58% for the day session. The total traded volume was 897,120. The stocks close on the previous trading day was $55.68.

Radius Health, Inc. is a science-driven biopharmaceutical company focused on developing therapeutics for patients with osteoporosis, as well as other serious endocrine-mediated diseases. The Companys lead product candidate is abaloparatide (BA058), a bone anabolic for use in the reduction of fractures in postmenopausal osteoporosis delivered through subcutaneous injection, which it refers to as abaloparatide-SC and is in Phase III development. The Company is leveraging its investment in Abaloparatide-SC to develop a line extension that is designed to improve patient convenience by enabling administration of abaloparatide through an investigational short-wear-time patch, which the Company refers to as abaloparatide-TD. The Companys clinical product portfolio also includes the investigational drug RAD1901, a selective estrogen receptor down regulator/degrader (SERD) and RAD140, a nonsteroidal selective androgen receptor modulator (SARM), for the treatment of breast cancer.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.